Volume 20, Number 6—June 2014
CME ACTIVITY - Synopsis
Adverse Pregnancy Outcomes and Coxiella burnetii Antibodies in Pregnant Women, Denmark
Table 2
Pt and preg | First sample |
Last sample |
Comments | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Date collected† | Titers |
Date collected† | Titers |
||||||||||
IgM II | IgM I | IgG II | IgG I | IgM II | IgM I | IgG II | IgG I | ||||||
Pt 1 |
7 wk |
2,048 |
8,000 |
1,024 |
512 |
38 wk |
<64 |
<64 |
256 |
<128 |
Negative titers 6 mo before this preg |
||
Pt 2 |
8 wk, after miscarriage |
256 |
<64 |
256 |
128 |
7 wk, after extrauterine preg |
512 |
128 |
512 |
512 |
Maximum titers after second miscarriage: IgG phase II, 4,096; IgG phase I, 2,048; IgM phase I, 512; IgM phase II, 256 |
||
Pt 3 |
3 wk |
<64 |
<64 |
<128 |
512 |
33 |
<64 |
<64 |
128 |
1,024 |
First titers taken 2 mo before this preg: IgG phase I, 1,024. Maximum titers in preg week 9: IgG phase I, 4,096; IgG phase II, 256‡ |
||
Pt 4 |
10 wk |
<64 |
<64 |
1,024 |
512 |
1 day postpartum |
<64 |
<64 |
1,024 |
128 |
First titers taken 3 mo before this preg identical to titers from preg week 10§ |
||
Pt 5 | |||||||||||||
Preg 1 | 9 wk | <64 | <64 | 256 | 512 | 38 wk | <64 | <64 | 256 | 256 | First titers taken 6 mo before this preg: IgM phase II, <64; IgM phase I, <64; IgG phase II, 512; IgG phase I, 1,024§ | ||
Preg 2 |
12 wk |
<64 |
<64 |
128 |
1,024 |
31 wk |
<64 |
<64 |
512 |
1,024 |
§ |
||
Pt 6 |
13 wk |
<64 |
<64 |
256 |
<128 |
At birth |
<64 |
<64 |
128 |
<128 |
No titers available before this preg. Maximum titers in preg: IgG phase II, 256‡ |
||
Pt 7 |
8 wk |
128 |
<64 |
4,096 |
<128 |
At birth |
64 |
<64 |
512 |
<128 |
Titers positive 6 mo before this preg: IgM phase II, 128; IgM phase I, <64; IgG phase II, 2048; IgG phase I, <128§ |
||
Pt 8 | |||||||||||||
Preg 1 | 12 wk | 128 | <64 | 512 | 256 | 26 wk | 256 | <64 | 1,024 | 256 | Maximum titers in this preg: IgG phase II, 2,048‡ | ||
Preg 2 |
10 wk |
<64 |
<64 |
256 |
128 |
26 wk |
<64 |
<64 |
256 |
256 |
Maximum titers in this preg: IgG phase I, 1,024; IgG phase II, 1,024‡ |
||
Pt 9 | |||||||||||||
Preg 1 | 10 wk | <64 | <64 | 256 | <128 | 39 wk | 64 | <64 | 128 | <128 | Maximum titers in this preg: phase II IgG, 1,024‡ | ||
Preg 2 |
12 wk |
<64 |
<64 |
256 |
<128 |
36 wk |
<64 |
<64 |
256 |
<128 |
§ |
||
Pt 10 | |||||||||||||
Preg 1 | 8 wk | 512 | <64 | 4,096 | <128 | 36 wk | <64 | <164 | 256 | <128 | No titers available before this preg§ | ||
Preg 2 |
9 wk |
<64 |
<64 |
128 |
<128 |
14 wk |
<64 |
<64 |
<128 |
<128 |
§ |
||
Pt 11 |
7 wk |
<64 |
<64 |
128 |
128 |
26 wk |
256 |
256 |
512 |
<128 |
Titers positive 1 mo before this preg: IgM phase II, <64; IgM phase I, <64; IgG phase II, 1,024; IgG phase I, <128§ |
||
Pt 12 | 10 wk | <64 | <64 | 2,048 | <128 | 37 wk | <64 | <64 | 1,024 | 1,024 | Negative titers during preg 2 years earlier. Maximum titers in this preg: IgG phase II, 2,048 |
*See Table 1 for specific patient and outcome data. Pt, patient; preg, pregnancy; vet, veterinarian; NA, not applicable; IUGR, intrauterine growth restriction.
†Gestational week.
‡Remaining titers have not risen above/beyond values in beginning/end of pregnancy.
§No further rise of titers in this pregnancy; indicates that titers had not risen beyond values at beginning/end of pregnancy.
Page created: May 14, 2014
Page updated: May 14, 2014
Page reviewed: May 14, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.